# A Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function

> **NCT02443155** · PHASE2 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 308 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 1

## Interventions

- **DRUG:** NNC0114-0006
- **DRUG:** liraglutide
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT02443155
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11-10
- **Primary completion:** 2018-08-31
- **Final completion:** 2019-02-27
- **Target enrollment:** 308 (ACTUAL)
- **Last updated:** 2021-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02443155

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02443155, "A Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02443155. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*